IFNA2 and COVID-19: The first trial registered on January 23, 2020 was a randomized controlled trial titled “A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19),” and was sponsored by the Wuhan Jinyintan Hospital.